NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a Company developing proprietary carbohydrate-based therapeutic compounds to treat cancer and fibrosis, today announced two of its executives and a member of its Scientific Advisory Board edited a new book “Galectins” and authored one of the chapters. The book offers a comprehensive guide to the current understanding of galectins, their promising potential in drug design and the role galectins play in tumor growth, cancer, angiogenesis, resistance to chemotherapy, and the initiation and proliferation of organ fibrosis.
